C([O:3][C:4](=O)[CH2:5][C:6]1[C:11]([Cl:12])=[CH:10][N:9]=[C:8]([N:13]2[CH2:18][CH2:17][N:16]([CH3:19])[CH2:15][CH2:14]2)[CH:7]=1)C.C([NH2:23])=O.C[O-].[Na+].[O-]S([O-])(=O)=O.[Na+].[Na+]>CN(C=O)C.CO.C(Cl)Cl.O>[Cl:12][C:11]1[C:6]([CH2:5][C:4]([NH2:23])=[O:3])=[CH:7][C:8]([N:13]2[CH2:18][CH2:17][N:16]([CH3:19])[CH2:15][CH2:14]2)=[N:9][CH:10]=1[5-Chloro-2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-acetic acid ethyl ester (385 mg, 1.29 mmol) is dissolved under an atmosphere of argon in dry DMF (4 ml). Formamide (195 mg, 4.33 mmol) is added, and the mixture is heated to 105° C. At this temperature, sodium methoxide (5.4 M in MeOH, 0.24 ml, 1.29 mmol) is added dropwise. After 20 minutes, TLC analysis indicated incomplete conversion, thus another addition of sodium methoxide (0.08 ml of a 5.4 M solution in MeOH) is done. After a further 10 minutes, the reaction is judged complete according to TLC. The reaction mixture is cooled to RT and diluted with CH2Cl2 (150 ml). Water is added (3 ml) until a clear solution is obtained. Sufficient Na2SO4 is added to absorb the water and the organic solvent is evaporated. The residue is purified by FCC (CH2Cl2/MeOH 95:5 to 80:20) to afford the title compound. 1H NMR (CDCl3, 400 MHz): δ 2.35 (s, 3H), 2.51 (m, 4H), 3.56 (m, 4H), 3.62 (s, 2H), 5.37 (s, broad, 1H), 5.54 (s, broad, 1H), 6.64 (s, 1H), 8.15 (s, 1H). ES+−MS: 269.2, 271.1 (Cl) [M+H]+, ES−−MS: 267.2, 269.3 (Cl) [M−H]−.
読み込み中…
